EfTEN United Property Fund's H1 2025 results were based on a fully invested portfolio. In addition, the property development investment in the fund's subsidiary Invego Uus-Järveküla OÜ has reached the stage where the completed terraced and semi-detached houses are being handed over to customers. Supported by the signing of real-right agreements at the Uus-Järveküla development, the fund's half-year profit increased more than fourfold compared to the same period of the previous year, and the fund made the historically largest cash distribution to investors, amounting to approximately 7% of the fund's market price.
STAMFORD, Ct, Aug. 04, 2025 (GLOBE NEWSWIRE) -- HCM III Acquisition Corp (Nasdaq: HCMAU) (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today the closing of its previously announced initial public offering of 25,300,000 units, including 3,300,000 units issued pursuant to the full exercise by the underwriter of its over-allotment option. The units were sold at a price of $10.00 per unit. The Company’s units began trading on August 1, 2025 on the Nasdaq Global Market under the symbol “HCMAU”. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. Each whole warrant is exercisable to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq Global Market under the ticker symbols “HCMA” and “HCMAW,” respectively.
SAN DIEGO, Aug. 4, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit...
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Neogen Corporation (NASDAQ: NEOG) common stock between January 5, 2023 and June 3, 2025, inclusive (the “Class Period”), have until Tuesday, September 16, 2025 to seek appointment as lead plaintiff of the Neogen class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation, No. 25-cv-00802 (W.D. Mich.), the Neogen class action lawsuit charges Neogen and certain of Neogen’s top executives with violations of the Securities Exchange Act of 1934.
VICTORIA, Seychelles, Aug. 03, 2025 (GLOBE NEWSWIRE) -- A Bitget, principal corretora de criptomoedas e empresa Web3 do mundo, lançou seu novo recurso de compra recorrente, que permite um plano de investimento sistemático, possibilitando aos usuários agendar aquisições automatizadas de criptomoedas usando os cartões Visa e Mastercard. O recurso foi desenvolvido para ajudar os usuários a criarem portfólios de criptomoedas de longo prazo com o mínimo de esforço, aplicando uma estratégia comprovada, conhecida como Dollar Cost Averaging (DCA) — um método que historicamente gerou retornos de até 30% ou mais em ciclos de mercado em alta.
SAN DIEGO, Aug. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.).
SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fiserv, Inc. (NYSE: FI) common stock between July 24, 2024 and July 22, 2025, inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Fiserv class action lawsuit. Captioned City of Hollywood Police Officers’ Retirement System v. Fiserv, Inc., No. 25-cv-06094 (S.D.N.Y.), the Fiserv class action lawsuit charges Fiserv as well as certain of Fiserv’s top current and former executives with violations of the Securities Exchange Act of 1934.
NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars...
SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lockheed Martin Corporation (NYSE: LMT) securities between January 23, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), have until September 26, 2025 to seek appointment as lead plaintiff of the Lockheed Martin class action lawsuit. Captioned Khan v. Lockheed Martin Corporation, No. 25-cv-06197 (S.D.N.Y.), the Lockheed Martin class action lawsuit charges Lockheed Martin and certain of Lockheed Martin’s top current and former executives with violations of the Securities Exchange Act of 1934.
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.
Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs
Respective Generics Businesses and Endo's Sterile Injectables Business to be Combined and Spun...